Search

Relatlimab

[L41265,L41300] It was the first anti-LAG-3 antibody to demonstrate benefit in a Phase 3 study, as well as the first to receive FDA approval. … efficacy when used alone, drugs like relatlimab have been trialed in combination with other checkpoint inhibitors - for example, PD-1 inhibitors like [nivolumab] or CTLA-4 inhibitors like [ipilimumab] - to

Chlorothiazide

A thiazide diuretic with actions and uses similar to those of hydrochlorothiazide. (From Martindale, The Extra Pharmacopoeia, 30th ed, p812)

Mogamulizumab

Approval in Japan was granted on April 30 2012 by the Japanese Ministry of Health, Labour and Welfare for patients with relapsed or refractory CCR4-positive adult T-cell leukemia-lymphoma.[A36741] … [L4170] On August 8 2018, the U.S.

Tepoxalin

It is primarily used to reduce inflammation and relief of pain caused by musculoskeletal disorders such as hip dysplasia and arthritis.

PPI-1019

Apan (PPI-1019) is developed by Praecis Pharmaceuticals to treat Alzheimer's Disease.

Cloxazolam

Cloxazolam is a benzodiazepine with anxiolytic, sedative/hypnotic, muscle relaxant, and antiepileptic effects. It is marketed in the Argentina, Australia, Portugal, Belgium, Switzerland, Luxembourg, Germany, Taiwan and Japan -- mainly fo...

Efinaconazole

It was approved for use in Canada and the USA in 2014 and is marketed by Valeant Pharmaceuticals North America LLC under the name Jublia.

Aluminium phosphate

Carboplatin

[A230463,A230523] Carboplatin was granted FDA approval on 3 March 1989.[L32248]

Mexiletine

Antiarrhythmic agent pharmacologically similar to lidocaine. It may have some anticonvulsant properties.